Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 921-928

  Miyamae, Yohei ^a   Shimizu, Kimihiro ^a   Hirato, Junko ^b   Araki, Takuya ^a   Tanaka, Kazumi ^a   Ogawa, Hiroomi ^a   Kakegawa, Seiichi ^a   Sugano, Masayuki ^a   Nakano, Tetsuhiro ^a   Mitani, Yasumasa ^c   Kaira, Kyoichi ^a   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c KK DNAFORM   (Japan)

Author keywords

EGFR mutation; Non small cell lung cancer; SmartAmp2; Squamous cell carcinoma

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOSQUAMOUS CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RECEPTOR GENE; SEQUENCE ANALYSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952232123     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1182     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
3. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
4. Zhu CQ, da Cunha Santos G, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
5. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004. (Pubitemid 39665498)
6. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005. (Pubitemid 46224186)
7. Soung YH, Lee JW, Kim SY, et al: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446: 483-488, 2005.
8. Sugio K, Uramoto H, Ono K, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94: 896-903, 2006.
9. Tomizawa Y, Iijima H, Sunaga N, et al: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11: 6816-6822, 2005. (Pubitemid 41428736)
10. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
11. Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262, 2006. (Pubitemid 41779062)
12. Wiwanitkit V: Squamous cell carcinoma of the lung: pattern of epidermal growth factor receptor mutation distribution in different populations: a summary. Lung 184: 301-302, 2006.
13. Sasaki H, Endo K, Mizuno K, et al: EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 51: 135-136, 2006. (Pubitemid 43088635)
14. Tatematsu A, Shimizu J, Murakami Y, et al: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14: 6092-6096, 2008.
15. Janne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12: 751-758, 2006. (Pubitemid 43259854)
16. Miyamae Y, Shimizu K, Mitani Y, et al: Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn 12: 257-264, 2010.
17. Araki T, Shimizu K, Nakamura K, et al: Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn 12: 118-124, 2010.
18. Mitani Y, Lezhava A, Kawai Y, et al: Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat Methods 4: 257-262, 2007. (Pubitemid 46358877)
19. Cao W, Hashibe M, Rao JY, Morgenstern H and Zhang ZF: Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 27: 397-404, 2003. (Pubitemid 37365555)
20. Tatsumi K, Mitani Y, Watanabe J, et al: Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn 10: 520-526, 2008.
21. Yu J, Kane S, Wu J, et al: Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15: 3023-3028, 2009.
22. Brevet M, Arcila M and Ladanyi M: Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12: 169-176, 2010.
23. Kargi A, Gurel D and Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 15: 415-420, 2007.
24. Khayyata S, Yun S, Pasha T, et al: Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 37: 178-183, 2009.
25. Kang SM, Kang HJ, Shin JH, et al: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 109: 581-587, 2007. (Pubitemid 46190967)
26. Ohtsuka K, Ohnishi H, Fujiwara M, et al: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 109: 741-750, 2007. (Pubitemid 46233236)
27. Ricciardi S, Tomao S and de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10: 28-35, 2009.
28. Stinchcombe TE and Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6: 233-241, 2009.
29. Chua YJ, Steer C and Yip D: Recent advances in management of small-cell lung cancer. Cancer Treat Rev 30: 521-543, 2004. (Pubitemid 39157853)
30. Sandler A and Herbst R: Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12: 4421S-4425S, 2006.
31. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006. (Pubitemid 44917502)
32. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191, 2004. (Pubitemid 41095154)
33. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non- small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
34. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004. (Pubitemid 41079796)
35. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M and Fujii Y: Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 55: 129-130, 2007. (Pubitemid 46038873)
36. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005. (Pubitemid 47050841)
37. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
38. Takano T, Fukui T, Ohe Y, et al: EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595, 2008.
39. Park SH, Ha SY, Lee JI, et al: Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 24: 448-452, 2009.
40. Schreiber G and McCrory DC: Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 123: 115S-128S, 2003.
41. Burnett RA, Howatson SR, Lang S, et al: Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens. J Clin Pathol 49: 130-133, 1996. (Pubitemid 26064918)
42. Thomas JS, Lamb D, Ashcroft T, et al: How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 48: 1135-1139, 1993. (Pubitemid 23336832)
43. Vollmer RT, Ogden L and Crissman JD: Separation of small-cell from non-small-cell lung cancer. The Southeastern Cancer Study Group pathologists' experience. Arch Pathol Lab Med 108: 792-794, 1984.
44. Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400, 2009.
45. Okami J, Taniguchi K, Higashiyama M, et al: Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 72: 234-242, 2007. (Pubitemid 351161616)
46. He C, Liu M, Zhou C, et al: Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 125: 2393-2399, 2009.